share_log

HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES 將參加第 23 屆年度 NEEDHAM 虛擬醫療會議
PR Newswire ·  03/26 08:05

PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m. ET.

賓夕法尼亞州普利茅斯會議,2024年3月26日 /PRNewswire/ — Harmony Biosciences Holdings, Inc.(納斯達克股票代碼:HRMY)今天宣佈,Harmony的管理團隊將在即將到來的23日參加爐邊談話第三方 年度Needham虛擬醫療會議將於美國東部時間2024年4月8日星期一上午9點30分舉行。

A webcast of the fireside chat will be available on the investor page of Harmony's website at

爐邊談話的網絡直播將在Harmony網站的投資者頁面上播出,網址爲

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit .

關於和諧生物科學
在Harmony Biosciences,我們專門開發和提供其他人經常忽視的罕見神經系統疾病的治療方法。我們相信,在同理心和創新相遇的地方,神經系統疾病患者可以開始更美好的生活。我們由Paragon Biosciences, LLC於2017年成立,總部位於賓夕法尼亞州普利茅斯會議。我們的專家團隊由來自不同學科和經驗的專家組成,我們的共同信念是,創新科學可以轉化爲患者的治療可能性,而患者是我們所做一切的核心。欲了解更多信息,請訪問。

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
[email protected]

和諧生物科學投資者聯繫方式:
路易斯·薩奈,特許金融分析師
445-235-8386
[電子郵件保護]

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
[email protected]

和諧生物科學媒體聯繫人:
凱特·麥坎利斯
202-641-6086
[電子郵件保護]

SOURCE Harmony Biosciences

來源 Harmony Bios

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論